Close Menu

NEW YORK (360Dx) – A diagnostic test used by Mayo Clinic to detect a rare neurological disease involves standard techniques and is not subject to patent law, a federal appeals court ruled Wednesday.

The appellate court's decision to uphold a district court ruling in the patent dispute effectively denied claims by Quest Diagnostics' Athena Diagnostics division that it was owed royalties for the testing. The US Court of Appeals for the Federal Circuit sided with Mayo in a 2-1 decision.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.